• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性骨髓纤维化中的DNA甲基化部分与驱动突变相关,且与其他髓系恶性肿瘤不同。

DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies.

作者信息

Dursun Torlak Esra, Tharmapalan Vithurithra, Kricheldorf Kim, Schifflers Joelle, Caduc Madeline, Zenke Martin, Koschmieder Steffen, Wagner Wolfgang

机构信息

Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany.

Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical School, 52074, Aachen, Germany.

出版信息

Clin Epigenetics. 2025 May 3;17(1):72. doi: 10.1186/s13148-025-01877-1.

DOI:10.1186/s13148-025-01877-1
PMID:40319310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12048995/
Abstract

BACKGROUND

Primary myelofibrosis (PMF) is a clonal blood disorder characterized by mutually exclusive driver mutations in JAK2, CALR, or MPL genes. So far, it is largely unclear if the driver mutations have a specific impact on DNA methylation (DNAm) profiles and how epigenetic alterations in PMF are related to other myeloid malignancies.

RESULTS

When we compared DNAm profiles from PMF patients we found very similar epigenetic modifications in JAK2 and CALR mutated cases, whereas MPL mutations displayed less pronounced and distinct patterns. Furthermore, induced pluripotent stem cell (iPSC) models with JAK2 mutations indicated only a moderate association with PMF-related epigenetic changes, suggesting that these alterations may not be directly driven by the mutations themselves. Additionally, PMF-associated epigenetic changes showed minimal correlation with allele burden and seemed to be largely influenced by shifts in the cellular composition. PMF DNAm profiles compared with those from other myeloid malignancies-such as acute myeloid leukemia, juvenile myelomonocytic leukemia, and myelodysplastic syndrome-showed numerous overlapping changes, making it difficult to distinguish PMF based on individual CpGs. However, a PMF score created by combining five CpGs was able to discern PMF from other diseases.

CONCLUSION

These findings demonstrate that PMF driver mutations do not directly evoke epigenetic changes. While PMF shares epigenetic alterations with other myeloid malignancies, DNA methylation patterns can distinguish between PMF and related diseases.

摘要

背景

原发性骨髓纤维化(PMF)是一种克隆性血液疾病,其特征是JAK2、CALR或MPL基因存在相互排斥的驱动突变。到目前为止,驱动突变是否对DNA甲基化(DNAm)谱有特定影响以及PMF中的表观遗传改变与其他髓系恶性肿瘤如何相关,在很大程度上尚不清楚。

结果

当我们比较PMF患者的DNAm谱时,我们发现在JAK2和CALR突变病例中表观遗传修饰非常相似,而MPL突变表现出不太明显和独特的模式。此外,具有JAK2突变的诱导多能干细胞(iPSC)模型仅表明与PMF相关的表观遗传变化有适度关联,这表明这些改变可能不是由突变本身直接驱动的。此外,PMF相关的表观遗传变化与等位基因负担的相关性最小,似乎在很大程度上受细胞组成变化的影响。与其他髓系恶性肿瘤(如急性髓系白血病、青少年粒单核细胞白血病和骨髓增生异常综合征)的DNAm谱相比,PMF显示出许多重叠的变化,这使得基于单个CpG难以区分PMF。然而,通过组合五个CpG创建的PMF评分能够将PMF与其他疾病区分开来。

结论

这些发现表明,PMF驱动突变不会直接引发表观遗传变化。虽然PMF与其他髓系恶性肿瘤有共同的表观遗传改变,但DNA甲基化模式可以区分PMF和相关疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/a8533e10a143/13148_2025_1877_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/4bf830a359a1/13148_2025_1877_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/06de81778658/13148_2025_1877_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/99e65f78ddcb/13148_2025_1877_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/f2c60447a9e1/13148_2025_1877_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/319de2a9da80/13148_2025_1877_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/7bc4c36691ba/13148_2025_1877_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/a8533e10a143/13148_2025_1877_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/4bf830a359a1/13148_2025_1877_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/06de81778658/13148_2025_1877_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/99e65f78ddcb/13148_2025_1877_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/f2c60447a9e1/13148_2025_1877_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/319de2a9da80/13148_2025_1877_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/7bc4c36691ba/13148_2025_1877_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8061/12048995/a8533e10a143/13148_2025_1877_Fig7_HTML.jpg

相似文献

1
DNA methylation in primary myelofibrosis is partly associated with driver mutations and distinct from other myeloid malignancies.原发性骨髓纤维化中的DNA甲基化部分与驱动突变相关,且与其他髓系恶性肿瘤不同。
Clin Epigenetics. 2025 May 3;17(1):72. doi: 10.1186/s13148-025-01877-1.
2
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.韩国原发性血小板增多症和原发性骨髓纤维化患者的JAK2 V617F、MPL及CALR突变
J Korean Med Sci. 2015 Jul;30(7):882-8. doi: 10.3346/jkms.2015.30.7.882. Epub 2015 Jun 10.
3
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者(原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤)的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
4
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.JAK2、CALR或MPL驱动基因突变在原发性骨髓纤维化中的临床效应
Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.
5
The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.203 例台湾原发性骨髓纤维化患者中驱动基因突变的临床和预后相关性。
J Clin Pathol. 2018 Jun;71(6):514-521. doi: 10.1136/jclinpath-2017-204829. Epub 2017 Dec 4.
6
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].[BCR-ABL阴性骨髓增殖性肿瘤的遗传学特征]
Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):35-39. doi: 10.3760/cma.j.issn.0578-1426.2020.01.006.
7
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.经典骨髓增殖性肿瘤的遗传学基础和分子病理生理学。
Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27.
8
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.CALR 突变与 JAK2 突变、MPL 突变或三阴性骨髓纤维化的临床、细胞遗传学和分子比较。
Leukemia. 2014 Jul;28(7):1472-7. doi: 10.1038/leu.2014.3. Epub 2014 Jan 9.
9
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
10
Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm-A single-center study from North India.BCR:ABL1 阴性经典型骨髓增殖性肿瘤中驱动基因突变谱的患病率及临床病理特征——来自印度北部的一项单中心研究
Indian J Pathol Microbiol. 2024 Oct 1;67(4):739-746. doi: 10.4103/ijpm.ijpm_743_23. Epub 2024 Mar 25.

本文引用的文献

1
Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.钙网蛋白和JAK2V617F驱动突变在骨髓增殖性肿瘤中诱导不同的有丝分裂缺陷。
Sci Rep. 2024 Feb 2;14(1):2810. doi: 10.1038/s41598-024-53240-8.
2
Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.iPS 细胞来源的 JAK2 V617F 巨核细胞的促炎表型在体外骨髓龛 3D 中诱导纤维化。
Stem Cell Reports. 2024 Feb 13;19(2):224-238. doi: 10.1016/j.stemcr.2023.12.011. Epub 2024 Jan 25.
3
Epigenetic signature of ionizing radiation in therapy-related AML patients.
治疗相关急性髓系白血病患者电离辐射的表观遗传特征
Heliyon. 2023 Dec 2;10(1):e23244. doi: 10.1016/j.heliyon.2023.e23244. eCollection 2024 Jan 15.
4
UniBind: a novel artificial intelligence-based prediction model for SARS-CoV-2 infectivity and variant evolution.UniBind:一种基于人工智能的新型严重急性呼吸综合征冠状病毒2感染性和变异进化预测模型。
Signal Transduct Target Ther. 2023 Dec 19;8(1):464. doi: 10.1038/s41392-023-01691-2.
5
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms.骨髓增殖性肿瘤的恶性克隆中细胞衰老加速。
Blood Cancer J. 2023 Nov 6;13(1):164. doi: 10.1038/s41408-023-00936-1.
6
Targeted DNA Methylation Analysis Facilitates Leukocyte Counts in Dried Blood Samples.靶向 DNA 甲基化分析有助于干血斑样本中的白细胞计数。
Clin Chem. 2023 Nov 2;69(11):1283-1294. doi: 10.1093/clinchem/hvad143.
7
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.表观基因组分析揭示了GATA2缺乏症中异常的DNA甲基化特征。
Haematologica. 2023 Sep 1;108(9):2551-2557. doi: 10.3324/haematol.2022.282305.
8
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.造血过程中的表观遗传调控及其在血液系统恶性肿瘤靶向治疗中的意义。
Signal Transduct Target Ther. 2023 Feb 17;8(1):71. doi: 10.1038/s41392-023-01342-6.
9
Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.靶向白血病、骨髓增生异常综合征和淋巴瘤中的 DNA 甲基化:一种有潜在诊断、预后和治疗价值的工具。
Int J Mol Sci. 2022 Dec 30;24(1):633. doi: 10.3390/ijms24010633.
10
A DNA methylation atlas of normal human cell types.正常人类细胞类型的 DNA 甲基化图谱。
Nature. 2023 Jan;613(7943):355-364. doi: 10.1038/s41586-022-05580-6. Epub 2023 Jan 4.